NMPA Releases Plans to Support HK and Macau Drug, Device Production in Mainland Cities
The National Medical Products Administration (NMPA) has released two implementation plans aimed at supporting Hong...
July 2022
Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...
Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC
The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...
Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection
Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a...
Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing
China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...
NMPA Releases 55th Batch of Reference Drugs for Generic Evaluation
The National Medical Products Administration (NMPA) has released the 55th batch of reference drugs for...
BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study
BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...
NMPA Releases Work Plans for Temporary Import of Urgently Needed Drugs
The National Medical Products Administration (NMPA) has officially released the “Work Plan for the Temporary...
Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...
Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT
China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...
Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment
The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...